ES2085352T3 - Metodo y composicion para el tratamiento de la trombosis en un mamifero. - Google Patents

Metodo y composicion para el tratamiento de la trombosis en un mamifero.

Info

Publication number
ES2085352T3
ES2085352T3 ES90909024T ES90909024T ES2085352T3 ES 2085352 T3 ES2085352 T3 ES 2085352T3 ES 90909024 T ES90909024 T ES 90909024T ES 90909024 T ES90909024 T ES 90909024T ES 2085352 T3 ES2085352 T3 ES 2085352T3
Authority
ES
Spain
Prior art keywords
composition
mammal
nucleum
reducing
free
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90909024T
Other languages
English (en)
Inventor
Edgar O O'rear Iii
Philip D Nguyen
Arthur E Johnson
Eugene S Patterson
Thomas L Whitsett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Corp Technologies Inc
Original Assignee
Research Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Corp Technologies Inc filed Critical Research Corp Technologies Inc
Application granted granted Critical
Publication of ES2085352T3 publication Critical patent/ES2085352T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

UNA COMPOSICION QUE COMPRENDE UNA MULTITUD DE MICROCAPSULAS ADECUADAS PARA INYECCION PARENTERAL EN UN MAMIFERO QUE CONSTA DE UN NUCLEO CONTENIENDO ESTREPTOQUINASA, Y UNA CAPA BIOCOMPATIBLE SEMI-PERMEABLE QUE RODEA AL NUCLEO PERMITIENDO LA LIBERACION CONTROLADA DE AL MENOS UNA PORCION DE ESTREPTOQUINASA. ES UN METODO DE REDUCIR EL TIEMPO EXIGIDO PARA LA REPERFUSION DE UNA ARTERIA QUE CONTENGA UN TROMBO Y UN METODO DE REDUCIR EL REQUERIMIENTO DE DOSIS ESTANDAR DE UN ACTIVADOR PLASMINOGENO EN UN MAMIFERO COMPRENDIENDO LA INYECCION INTRAVENOSA DE UNA COMPOSICION QUE CONSTA DE UNA MULTITUD DE MICROCAPSULAS COMPUESTAS DE UN NUCLEO ACTIVADOR PLASMINOGENO MEDIANTE UNA CAPA SEMI-PERMEABLE DE LIBERACION CONTROLADA.
ES90909024T 1989-05-17 1990-05-15 Metodo y composicion para el tratamiento de la trombosis en un mamifero. Expired - Lifetime ES2085352T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35369389A 1989-05-17 1989-05-17

Publications (1)

Publication Number Publication Date
ES2085352T3 true ES2085352T3 (es) 1996-06-01

Family

ID=23390149

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90909024T Expired - Lifetime ES2085352T3 (es) 1989-05-17 1990-05-15 Metodo y composicion para el tratamiento de la trombosis en un mamifero.

Country Status (10)

Country Link
US (1) US5503850A (es)
EP (1) EP0472657B1 (es)
JP (1) JPH05501855A (es)
AT (1) ATE135200T1 (es)
AU (1) AU635541B2 (es)
CA (1) CA2016949C (es)
DE (1) DE69025934T2 (es)
DK (1) DK0472657T3 (es)
ES (1) ES2085352T3 (es)
WO (1) WO1990014078A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6461640B1 (en) 1995-12-08 2002-10-08 Board Of Regents, The University Of Texas System Local delivery of fibrinolysis enhancing agents
KR19980067002A (ko) * 1997-01-30 1998-10-15 김종국 스트렙토키나제를 리포좀에 봉입하여 얻는 혈중체류성 혈전용해제 및 그 제조방법
US6586011B2 (en) * 1999-06-10 2003-07-01 Southpac Trust International, Inc. Microencapsulated plasminogen activators
PT1438065E (pt) * 2001-10-01 2013-01-24 Matrizyme Pharma Corp Utilização de colagenase para facilitar a passagem de um passa-fios em oclusões crónicas das artérias
AU2003298738A1 (en) * 2002-11-26 2004-06-18 Su-Ming Chiang Liposomal formulations
US9814672B2 (en) * 2007-03-09 2017-11-14 Susan T. Laing Echogenic vehicle for clinical delivery of plasminogen activator and other fibrin-binding therapeutics to thrombi

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH588887A5 (es) * 1974-07-19 1977-06-15 Battelle Memorial Institute
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS54147916A (en) * 1978-05-12 1979-11-19 Sumitomo Chem Co Ltd Preparation of urokinase injection
EP0028489B1 (en) * 1979-11-05 1983-10-05 Beecham Group Plc Enzyme derivatives, and their preparation
JPS574913A (en) * 1980-06-11 1982-01-11 Green Cross Corp:The Urokinase preparation for oral administration
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
JPS58222410A (ja) * 1982-06-19 1983-12-24 Mitsubishi Electric Corp ２進デ−タの記録再生装置
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
JPS59222410A (ja) * 1983-06-01 1984-12-14 Terumo Corp 薬物保持リポソ−ム製剤
JPS60215633A (ja) * 1984-04-11 1985-10-29 Terumo Corp 腸管吸収性ウロキナ−ゼリポソ−ム組成物
DE3474511D1 (en) * 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
JPS60155109A (ja) * 1984-01-23 1985-08-15 Terumo Corp リポソ−ム製剤
DE3584902D1 (de) * 1984-02-29 1992-01-30 Asahi Chemical Ind Waessrige loesung eines darin in erhoehter konzentration aufgeloesten gewebe-plasminogen-aktivators und herstellungsverfahren.
JPS60231609A (ja) * 1984-04-28 1985-11-18 Terumo Corp リポソ−ム製剤
JPS61353A (ja) * 1984-06-13 1986-01-06 テルモ株式会社 薬剤投与装置
JPS6176414A (ja) * 1984-09-21 1986-04-18 Shionogi & Co Ltd リポソーム製剤の製法
NL8503097A (nl) * 1985-11-11 1987-06-01 Leuven Res & Dev Vzw Geneesmiddel met thrombolytische werking.
KR870005646A (ko) * 1985-12-16 1987-07-06 로버트 엘. 미니어 수술후 유착형성 억제방법
WO1987006836A1 (en) * 1986-05-15 1987-11-19 Emory University Fibrinolytic composition
US4861597A (en) * 1986-05-20 1989-08-29 Wako Pure Chemical Industries, Ltd. Novel functionallized liposomes and a process for production thereof
JPH01115164A (ja) * 1987-10-28 1989-05-08 Oki Electric Ind Co Ltd 半導体装置
US5000887A (en) * 1988-05-17 1991-03-19 Liposome Technology, Inc. Preparation of uniform-size liposomes

Also Published As

Publication number Publication date
DK0472657T3 (da) 1996-06-17
WO1990014078A1 (en) 1990-11-29
DE69025934T2 (de) 1996-09-19
EP0472657A4 (en) 1992-07-08
CA2016949A1 (en) 1990-11-17
CA2016949C (en) 1996-12-10
AU635541B2 (en) 1993-03-25
ATE135200T1 (de) 1996-03-15
EP0472657A1 (en) 1992-03-04
DE69025934D1 (de) 1996-04-18
US5503850A (en) 1996-04-02
AU5810590A (en) 1990-12-18
JPH05501855A (ja) 1993-04-08
EP0472657B1 (en) 1996-03-13

Similar Documents

Publication Publication Date Title
ES2018729A6 (es) Un metodo para preparar una variante de activador de plasmogeno de tejido.
DK0719154T3 (da) Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel
DE69019084D1 (de) Methoden zur Verhinderung von Schimmel.
NO885109D0 (no) FremgangsmŸte og middel for Ÿ forhindre blodpropp.
DE3584902D1 (de) Waessrige loesung eines darin in erhoehter konzentration aufgeloesten gewebe-plasminogen-aktivators und herstellungsverfahren.
EP0876387A4 (en) PROCESS FOR IMPROVING THE BIOLOGICAL AND ANTIVIRAL ACTIVITY OF PROTEASE INHIBITORS
ATE212230T1 (de) Methoden zur krankheitsbehandlung unter verwendung von sertoli-zellen und allotransplantat oder xenotransplantat
DE69431358D1 (de) Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien
DK59991D0 (da) Ikke-peptid-renininhibitorer og fremgangsmaade til fremstilling deraf samt farmaceutisk middel indeholdende en saadan inhibitor
DE3874019D1 (de) Verfahren zur konservierung von transplantierbaren, in vitro kultivierten epithelgeweben.
DE3850531D1 (de) Gewebe-Plasminogenaktivator.
ES2085352T3 (es) Metodo y composicion para el tratamiento de la trombosis en un mamifero.
MX169931B (es) Procedimiento para determinar la catividad de serinproteasas inhibidores de serinproteasas
ES2047033T3 (es) Un metodo para preparar compuestos de hidroxivitamina d.
DK354188D0 (da) Guanidinothiazolforbindelse, fremgangsmaade til d eres fremstilling samt anvendelsen heraf som mellemprodukt i famotidinprocessen
FI881713L (fi) Menetelmä urokinaasityyppisen plasminogeenin aktivaattorin tuottamiseksi
DK381288D0 (da) Fremgangsmaade og anordning til maaling af vaevsplasminogenaktivator (t-pa) aktivitet
ATE244011T1 (de) Unterdrückung der thromboxanspiegel durch perkutane verabreichung von aspirin
ES2052670T3 (es) Utilizacion de derivados de 2-pirimidinil-1-piperazina.
ES2067221T3 (es) Activador de plasminogeno del tejido que tiene propiedades especificas para la fibrina.
DE3852118D1 (de) Protease-ähnliche zytotoxische lymphozyten-spezifische moleküle und verfahren.
DE60032114D1 (de) Behandlungsmethode von aknepatienten durch verabreichung von hemmern der cyclischen gmp pde
DE69127346D1 (de) Behandlung thrombotischer ereignisse
ATE133712T1 (de) Verfahren zum nachweis von plasminogen- aktivatoren, deren inhibitoren oder stimulatoren
DK0429324T3 (da) Anvendelse af N-methyl-2-(3pyridyl)-tetrahydrothiopyran-2-carbothioamid-1-oxid til fremstilling af lægemidler beregnet til behandling af coronarinsufficiens

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 472657

Country of ref document: ES